



15 December 2022  
EMA/911829/2022  
Human Medicines Division

## Committee for Medicinal Products for Human Use (CHMP): Work Plan 2023

Adopted by the Committee on 15 December 2022

### Table of Contents

<b>1. Evaluation activities for human medicines</b> .....	<b>3</b>
1.1. Pre-authorisation activities .....	3
1.1.1. Scientific consultations involving other decision makers to facilitate optimisation of clinical evidence generation in drug development programmes .....	3
1.1.2. Contributing to Accelerating Clinical Trials in the EU (ACT EU) .....	3
1.2. Initial-evaluation activities .....	4
1.2.1. Benefit/Risk methodology and communication .....	4
1.2.2. Patients involvement in assessment work .....	5
1.2.3. Documenting medicines evaluation – an efficiency and stakeholder focus on the CHMP AR and the EPAR .....	6
1.2.4. Strengthening communication with down-stream decision makers about regulatory assessment .....	6
1.2.5. Digital technologies .....	7
1.2.6. Contribution of real-world data to evidence generation .....	8
1.2.7. Contribution of individual patient data to evidence generation .....	8
1.2.8. Strengthening the assessment of Companion Diagnostics .....	9
1.3. Other specialised areas and activities .....	10
1.3.1. Geriatric medicines strategy .....	10
<b>2. Horizontal activities and other areas</b> .....	<b>10</b>
2.1. Committees and working parties .....	10
2.1.1. Special populations and product guidance .....	10
2.2. Partners and stakeholders .....	11
2.2.1. International Regulatory Science Cooperation .....	11



***The activities outlined in the CHMP work plan for 2023 have been agreed taking into consideration the Agency's prioritisation set forth in the EMA multi-annual work programme 2023-2025***

# 1. Evaluation activities for human medicines

## 1.1. Pre-authorisation activities

### 1.1.1. Scientific consultations involving other decision makers to facilitate optimisation of clinical evidence generation in drug development programmes

Clinical evidence generated during drug development is intended to serve different decision making. It is therefore desirable that evidence requirements do address regulatory needs as well as those of other down-stream decision makers.

#### Key objectives

- To engage with other decision makers in multi-stakeholder consultations on evidence generation planning.

#### Activities in 2023

CHMP activities to achieve the objectives set for this area:

- Collaborate with HTA bodies on prospective evidence planning for development programmes through provisions of parallel EMA/HTA scientific advice until the new HTA Regulation is in operation.
- Explore with healthcare payers opportunities for sharing views on prospective evidence planning, focusing on post-licensing evidence needs.

CHMP topic leader: Bruno Sepodes

Other contributors:

Member/alternate	Name	MS
Member	Johann Lodewijk Hillege	NL
SAWP Chair	Paolo Foggi	IT
Member	Helena Panayiotopoulou	CY

### 1.1.2. Contributing to Accelerating Clinical Trials in the EU (ACT EU)

In accordance with the CHMP mandate, CHMP provides advice for undertakings on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of medicinal products particularly regarding the development of new therapies.

Clinical Trial applications are in the remit of the member state where the application has been submitted.

Given the complex nature of medicines development, advice on closely related aspects of clinical trials being given by different regulatory actors, and the importance of building a consensus regulatory view in an efficient way, the objective is to develop a consolidated scientific advice process.

#### Key objectives

- Optimise European scientific advice through provision of consolidated scientific advice, bringing advice for clinical trial authorisation and for evidence to support marketing authorisation together, respecting roles and remits.

- As a first focus for consolidated advices and strengthening of scientific advice, to deliver the best evidence for decision making, in particular, for unmet medical needs, rare diseases, and on vaccines and therapeutics for public health crises and pandemics, with an emphasis on multinational clinical trials, where appropriate.

### Activities in 2023

- As part of ACT EU priority action 7 on scientific advice, to support via the SAWP and the ETF, and collaborating with EMRN, the development of a consolidated advice process across relevant clinical trial regulatory stakeholders, respecting roles and remits.
- Provide input to the development of a methodology guidance roadmap in collaboration with ACT EU priority action 8 and the Methodology Working Party.

CHMP topic leader: Ewa Iskra Balkowiec

Other contributors:

Member/alternate	Name	MS
Member	Blanca Garcia-Ochoa	ES

## 1.2. Initial-evaluation activities

### 1.2.1. Benefit/Risk methodology and communication

#### Activity areas

Benefits and risks require continuous evaluation throughout the lifecycle of a medicine. The objective is to balance benefits and risks in a way that is as robust, consistent and transparent as possible.

#### Key objectives

- Continued overview of developments in assessing and communicating benefits and risks. Develop training material about assessing and communicating benefits and risks.
- Build assessors' knowledge and experience with different approaches and describing value-judgments in the current benefit risk assessment framework/template.

### Activities in 2023

CHMP activities to achieve the objectives set for this area:

- To produce a reflection paper on single-arm trials that are submitted as pivotal evidence in marketing authorisation dossiers across therapeutic areas and publish it for public consultation.
- To produce training material on benefit-risk assessment and communication in the new optimised assessment report templates (see 1.2.3).
- Set up a focus study in collaboration with CAT committee to explore the usefulness of preference elicitation in the context of advisory meetings with experts (e.g. SAGs, AHEGs).

CHMP topic leader: Johann Lodewijk Hillege

Other contributors:

Member/alternate	Name	MS
Chair	Harald Enzmann	DE
Alternate	Filip Josephson	SE
Co-opted member	Jan Mueller-Berghaus	DE
Vice-Chair	Bruno Sepodes	PT
Member	Kristina Dunder	SE
Member	Armando Genazzani	IT
Alternate	Christian Gartner	AT

### 1.2.2. Patients involvement in assessment work

The objective is to facilitate the collection and use of patient experience data, so their perspectives and preferences can be considered in benefit/risk evaluations and related activities, along the medicine regulatory lifecycle.

#### Key objectives

- Maintain current and explore additional processes to capture and include patient experience data within CHMP benefit/risk evaluations.

#### Activities in 2023

CHMP activities to achieve the objectives set for this area:

- Monitor and improve methodologies to capture input to CHMP procedures (including participation in oral explanations, written consultations, and full implementation of process for engaging with patient organisations at start of Marketing Authorisation Applications).
- To contribute to the elaboration of a reflection paper to provide advice on the best EU approach to generate and collect patient experience data.
- Explore how to better reflect in the assessment report the way that patient experience data is assessed and the rationale for acceptance/exclusion for benefit/risk decision-making.
- Participate in drafting of new ICH guidance on patient experience data and patient preference elicitation.

CHMP topic leaders: Fátima Ventura and Concepcion Prieto Yerro

Other contributors:

Member/alternate	Name	MS
Vice-Chair	Bruno Sepodes	PT
Alternate	Edward Laane	EE
Co-opted member	Carla Torre	PT

### 1.2.3. Documenting medicines evaluation – an efficiency and stakeholder focus on the CHMP AR and the EPAR

#### Activity areas

Improve/optimize the initial evaluations assessment report with the aim to simplify, avoid replication of work and meet/consider stakeholders' expectations. Examine the best use of available resources at CHMP and EMA to achieve this goal.

#### Key objectives

- Review ways to improve the efficiency, robustness, consistency and soundness of outputs throughout the initial MAA evaluation process.

#### Activities in 2023

CHMP activities to achieve the objectives set for this area:

- Optimize the related assessment report templates (e.g. benefit-risk section, efficacy section of overview template) to avoid duplication of information while facilitating inclusion of all relevant information (e.g. explanation of the therapeutic indication, efficacy and safety in subgroups and outcomes of SAG meetings and oral explanations).

CHMP topic leaders: Johann Lodewijk Hillege

Other contributors:

Member/alternate	Name	MS
Member	Kristina Dunder	SE
Member	Jayne Crowe	IE

### 1.2.4. Strengthening communication with down-stream decision makers about regulatory assessment

Recognising that the regulatory outcome is only one step along the path for access to patients, it is important that there is mutual understanding and appropriate knowledge sharing between decision makers. This would need to respect the various remits of the individual parties. It is expected that fostering exchanges between regulators and down-stream decision makers on product specific matters will enhance the access of innovative medicines for patients.

#### Key objectives

- Continuously strengthening communications with down-stream decision makers on the outcome of regulatory assessment.

#### Activities in 2023

CHMP activities to achieve the objectives set for this area:

- As part of the assessment report optimisation initiative (see 1.2.3), enhance usefulness of the final report as reference for down-stream decision makers.
- Facilitation of discussions between CHMP rapporteurs and HTA authors on selected approvals.

CHMP topic lead: Carla Torre

Other contributors:

Member/alternate	Name	MS
Member	Johann Lodewijk Hillege	NL
Vice-Chair	Bruno Sepodes	PT

### 1.2.5. Digital technologies

#### Activity areas

Meet the challenge of assessing the benefit/risk of the increasing number of medicines and outcome measures utilising digital technologies. This activity will foster expertise growth and cross-agency cooperation in a fast-developing field while respecting the remit of different stakeholders.

#### Key objectives

- Ensure coordination and dissemination of learnings from cases (advices, qualifications, MAAs) across EMA activities.
- Explore enhanced cooperation with Notified Bodies.

#### Activities in 2023

- Qualification of digital technologies: discuss all digital qualification procedures (with additional focus on procedures with AI elements) from Scientific Advice (SA) in CHMP by development of a Digital Technology framework; monitor marketing authorisation applications (MAAs)/extensions with digital aspects (including applications with AI elements) in general and discussions from SA. Feed learnings into discussions on possible future guidance development.
- Expand EMA expert base in the areas of digital, biomechanics and devices, to provide support to different activities, including evaluation and scientific advice.

CHMP topic leaders: Bruno Sepodes

Other contributors:

Member/alternate	Name	MS
Chair	Harald Enzmann	DE
Alternate	Fátima Ventura	PT
Member	Ewa Balkowiec Iskra	PL
Member	Martina Weise	DE
Expert	Sabine Mayrhofer	DE

### 1.2.6. Contribution of real-world data to evidence generation

Enhanced analysis of data from the development and real-world use of medicinal products has the potential to further support regulatory decision-making. In this area, real-world evidence (RWE) offers the possibility to provide an additional perspective on the use and performance of medicines in everyday clinical use, complementing the evidence obtained from randomised control trials.

Real-world evidence has the potential to enhance decision-making through the lifecycle of medicinal products.

#### Key objectives

- Identify real-world evidence use cases to support evidence generation in Scientific Advice (SA) and CHMP decision-making.
- Ensure expert advice and guidance on real-world evidence is available to support CHMP decision-making.

#### Activities in 2023

- Conduct the pilot initiated on RWE studies to support the provision of SA on the generation of robust RWE.
- Conduct the pilot on RWE studies to support CHMP decision-making (including the feasibility to provide RWE on disease epidemiology and standard of care in the elderly). Provide expert input to a review of the experience gained with RWE studies conducted across the regulatory network to support regulatory decision making.
- Expand the existing group of experts on RWE to broaden the support to CHMP and their associated working parties in regulatory activities through the Methodology ESEC.
- Develop a roadmap of RWE guidance to support high-quality RWE generation and improve the use of RWE for regulatory decision-making. Provide expert input in support to the development of guidance on use of RWE for regulatory purpose.

CHMP topic leaders: Alar Irs

Other contributors:

Member/alternate	Name	MS
Alternate	Christian Gartner	AT
Co-opted member	Carla Torre	PT

### 1.2.7. Contribution of individual patient data to evidence generation

Enhanced access to clinical trial data from the marketing authorisation (MA) dossier has the potential to further support regulatory decision-making. Targeted analysis and visualisation of 'raw data', i.e. individual patient data from clinical trials in an electronic structured format, will be piloted to understand its impact on benefit-risk assessment and regulatory decision-making through the lifecycle of medicinal products.

#### Key objectives

- Explore the analysis of raw data from MA dossiers to support the assessment of initial marketing authorisation applications and selected post-authorisation procedures.



## Activities in 2023

- Proceed with proof-of-concept pilots of analysis and visualisation of raw data from marketing authorisation dossiers to learn of the practicalities and benefits of such an approach.
- Expand Network Community on Raw Data to regularly share developments on the raw data proof-of-concept pilots and foster close collaboration across the Network into using raw data for regulatory decision-making.
- Produce the proof-of-concept pilots' interim report to reflect on the pilot conduct.

CHMP topic leaders: Christian Gartner

Other contributors:

Member/alternate	Name	MS
Co-opted member	Carla Torre	PT
SAWP	Bruno Delafont	FR
SAWP	Joerg Zinserling	DE

## 1.2.8. Strengthening the assessment of Companion Diagnostics

### Activity areas

As per the Regulation (EU) 2017/746, a companion diagnostic (CDx) is essential for defining patients' eligibility for specific treatment with a medicinal product. As part of the conformity assessment of a CDx, the notified body shall seek a scientific opinion on the suitability of the CDx with the concerned medicinal product(s) from the competent authorities in accordance with Directive 2001/83/EC before issuing an EU technical documentation assessment certificate or an EU type-examination certificate, or a supplement to them for the CDx. The CHMP seeks to strengthen the assessment process following first group of applications received in 2022.

### Key objectives

- Create a framework for identification of overarching issues in the assessment of CDx consultation procedures.
- Identify general principles that can be later used for training assessment teams and to update the procedural guidance or assessment templates.

## Activities in 2023

- Set up CDx peer review group at CHMP and a process for peer review to support assessment of CDx consultation procedures.

CHMP topic lead: Harald Enzmann

Other contributors (Proposed):

Member/alternate	Name	MS
Alternate	Fátima Ventura	PT

## **1.3. Other specialised areas and activities**

### **1.3.1. Geriatric medicines strategy**

The rapid aging of the population worldwide means that people over 80 years are the fastest growing subpopulation group. The EMA geriatric medicines strategy aims to ensure that the benefit/risk balance of medicines is researched and evaluated with respect to the epidemiology of the disease, and that findings are adequately reflected in the CHMP assessment documents.

#### **Key objectives**

- Make sure the geriatric population is addressed in CHMP assessment reports and product information.

#### **Activities in 2023**

- Perform an ex-post control on (post-pilot) recently approved initial marketing authorisations to monitor for geriatric information presentation in assessment reports.
- Review selected scientific advice and D-120 initial marketing authorisation reports to monitor for geriatric information intake.
- Propose amendments to assessment reports and guidance following CHMP review of recently approved and ongoing initial marketing authorisation applications.
- In the context of the CHMP pilot on RWE studies, investigate the feasibility to provide RWE on disease epidemiology and standard of care in the elderly to support the committee decision-making.

CHMP topic leader: Andrea Laslop

Other contributors:

<b>Member/alternate</b>	<b>Name</b>	<b>MS</b>
SAWP	Mario Miguel Rosa	PT
SAWP	Elina Rönnemaa	SE
Vice-Chair	Bruno Sepodes	PT
Member	Martine Trauffer	LU
Expert	Sabine Mayrhofer	DE
Co-opted Member	Carla Torre	PT

## **2. Horizontal activities and other areas**

### **2.1. Committees and working parties**

#### **2.1.1. Special populations and product guidance**

Certain specific population groups require consideration in the conduct of assessment. This topic channels the Committee's expertise into the development of population specific guidance in terms of risk assessment of medicinal products on human reproduction and lactation in collaboration with PRAC committee.

## Key objectives

- Strengthen assessment by industry and regulators through dedicated guidance on specific populations.
- Strengthen systematic generation of information on the benefits and risks of medicines in pregnancy and breastfeeding.

## Activities in 2023

- Provide expert input on the update of 'CHMP Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling'.

CHMP topic leader: Jan Mueller Berghaus

Other contributors:

Member/alternate	Name	MS
Member	Ewa Balkowiec Iskra	PL

## 2.2. Partners and stakeholders

### 2.2.1. International Regulatory Science Cooperation

Given the increasing complexity of global developments in the pharmaceutical sector there is a drive to achieve greater harmonisation, building a convergence of regulatory tools and standards worldwide to ensure that safe, effective and high-quality medicines are developed, registered and maintained in the most resource efficient manner whilst meeting high standards.

This cooperation is mandated by the globalisation of medicine: in its supply chains, its research and development and its expertise. Reliance, where an authority relies on work done by another authority but retains its full power of decision, is supported by EMA. A pilot **O**pening our **P**rocedures at **E**MA to **N**on-EU authorities (OPEN) was initiated in 2020 aiming to share scientific expertise to tackle common challenges on COVID-19 vaccines and therapeutics while enhancing transparency on regulatory decisions and promoting EU Regulatory System. The benefits and experience gathered during this pilot highlighted the advantages of collaboration across regulatory agencies. Recommendations are being considered to further develop OPEN scheme post-COVID era, including the extension of OPEN to antimicrobial products.

## Key objectives

- Facilitate the assessment of the same data by multiple authorities.
- Continue to develop a solid and agile framework that strengthens the collective scientific assessment.

## Activities in 2023

- Implement recommendations extracted from the pilot and consolidate OPEN scheme process with selected international collaborators.

CHMP topic leader: Sol Ruiz

Other contributors:

<b>Member/alternate</b>	<b>Name</b>	<b>MS</b>
Vice-Chair	Bruno Sepodes	PT
Member	Ewa Balkowiec Iskra	PL
Member	Outi Mäki-Ikola	FI
SAWP	Andrea Laslop	AT